Compare AU
Compare DRUG vs. IXI
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare ETF - Currency Hedged (DRUG) and the iShares Global Consumer Staples ETF (IXI). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | IXI | |
---|---|---|
Popularity | Low | Low |
Pearlers invested | 64 | 37 |
Median incremental investment | $943.50 | $996.75 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,969.68 | $2,079.22 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | IXI | |
---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | IXI.AX was created on 2006-09-12 by iShares. The fund's investment portfolio concentrates primarily on consumer staples equity. The fund aims to provide investors with the performance of the S&P Global 1200 Consumer Staples Sector Index, before fees and expenses. The index is designed to measure the performance of global consumer staples companies and may include large-, mid- or smallcapitalisation stocks. |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | ISHARES GLOBAL CONSUMER STAPLES ET (99.97 %) USD CASH (0.21 %) USD/AUD (0.00 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | Other (99.92 %) Communication Services (0.08 %) |
Top 3 countries | United States (23.96 %) Ireland (0.52 %) France (0.00 %) | United States (99.61 %) |
Management fee | 0.57 % | 0.4 % |
Key Summary
DRUG | IXI | |
---|---|---|
Issuer | BetaShares | iShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | S&P Global 1200 / Consumer Staples -SEC |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.4 % |
Price | $8.49 | $94.50 |
Size | $197.947 million | $139.475 million |
10Y return | N/A | 84.21 % |
Annual distribution yield (5Y) | 1.90 % | 2.18 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 11/03/2009 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | IXI | |
---|---|---|
Popularity | Low | Low |
Pearlers invested | 64 | 37 |
Median incremental investment | $943.50 | $996.75 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,969.68 | $2,079.22 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | IXI | |
---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | IXI |
---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |